Collegium's Pain Portfolio Faces Its First Test Without Guidance
Collegium Pharmaceutical (NASDAQ: COLL) reports second-quarter 2026 earnings before the market opens on August 6, 2026. With the specialty pharmaceutical company having delivered a strong earnings beat last quarter and analysts expecting modest year-over-year growth, investors will be watching closely to see if COLL can maintain its recent momentum in the competitive pain management market.
Part 1: Earnings Preview
Collegium Pharmaceutical is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of pain, with its flagship product Xtampza ER (extended-release oxycodone) serving as the primary revenue driver in the abuse-deterrent opioid market.
For the second quarter of 2026, analysts expect COLL to report earnings per share of $1.48 when it reports before the open on August 6. The company most recently reported $1.50 per share for the first quarter of 2026, which significantly exceeded the $1.23 consensus estimate by 21.95%. Compared to the same quarter last year when COLL earned $1.47 per share, the current estimate implies modest year-over-year growth of +0.68%.
Three key themes define this earnings story:
Commercial Execution and Market Share: Investors will scrutinize Xtampza ER's prescription trends and market penetration as the company competes in the evolving pain management landscape. Any commentary on formulary wins, payer access improvements, or competitive dynamics will be critical to assessing the sustainability of revenue growth.
Operating Leverage and Profitability: With COLL having demonstrated strong earnings beats in recent quarters, the market will focus on whether the company can continue expanding margins through operational efficiency while managing the cost structure of its commercial organization.
Pipeline Development and Capital Allocation: Following the company's shift away from R&D spending in recent years, investors will look for updates on business development activities, potential product line extensions, and how management plans to deploy capital to drive long-term growth beyond the core Xtampza franchise.
Analyst commentary ahead of the release reflects cautious optimism, with the consensus maintaining a buy-leaning stance despite some recent downgrades. The estimate range of $1.42 to $1.53 suggests relatively tight expectations, indicating analysts have converged on a similar view of the quarter's performance.
Part 2: Historical Earnings Performance
Collegium Pharmaceutical has demonstrated a pattern of significant earnings volatility over the past four quarters, with two substantial beats and two misses. The company reported $1.47 in Q2 2025, beating the $1.43 estimate by 2.80%, followed by an impressive $2.06 in Q3 2025 that crushed the $1.69 estimate by 21.89%. However, Q4 2025 brought a disappointment with $1.85 versus the $2.01 estimate, a miss of 7.96%. Most recently, Q1 2026 delivered another strong beat at $1.50 against the $1.23 estimate, exceeding expectations by 21.95%.
The pattern reveals a company capable of significant upside surprises, particularly in odd-numbered quarters, but also prone to occasional misses when expectations run high. The two most recent quarters show beats of 21.95% and 2.80% respectively, while the two quarters before that showed a miss of 7.96% followed by a beat of 21.89%. This inconsistency suggests that while COLL has operational strength, quarterly results can be influenced by factors that create earnings lumpiness—potentially related to prescription timing, payer dynamics, or inventory management in the distribution channel.
Heading into Q2 2026, the relatively modest estimate of $1.48 (compared to $1.50 last quarter) may reflect analyst caution following the pattern of volatility, potentially setting up for another beat if the company's commercial momentum continues.
| Quarter | EPS Estimate | EPS Actual | Surprise % | Beat/Miss |
|---|---|---|---|---|
| Jun 2025 | $1.43 | $1.47 | +2.80% | Beat |
| Sep 2025 | $1.69 | $2.06 | +21.89% | Beat |
| Dec 2025 | $2.01 | $1.85 | -7.96% | Miss |
| Mar 2026 | $1.23 | $1.50 | +21.95% | Beat |
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Collegium Pharmaceutical typically reports earnings before the market open, meaning Day 0 represents the first trading session where investors react to results, while Day +1 captures follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-07 | +$2.82 (+7.72%) | $3.77 (10.33%) | -$1.53 (-3.89%) | $2.89 (7.35%) |
| 2026-02-26 | -$1.53 (-3.34%) | $4.18 (9.14%) | -$2.55 (-5.77%) | $3.30 (7.45%) |
| 2025-11-06 | +$4.81 (+13.42%) | $2.73 (7.62%) | +$1.64 (+4.03%) | $2.47 (6.07%) |
| 2025-08-07 | +$3.19 (+10.72%) | $2.07 (6.96%) | +$1.99 (+6.04%) | $1.71 (5.19%) |
| 2025-05-08 | +$0.22 (+0.81%) | $1.16 (4.29%) | +$1.62 (+5.94%) | $1.82 (6.67%) |
| 2025-02-27 | +$0.07 (+0.25%) | $1.16 (4.09%) | +$0.63 (+2.22%) | $2.63 (9.25%) |
| 2024-11-07 | +$0.21 (+0.61%) | $1.28 (3.71%) | -$2.55 (-7.35%) | $2.34 (6.74%) |
| 2024-08-08 | +$0.67 (+1.93%) | $0.84 (2.42%) | +$0.18 (+0.51%) | $1.15 (3.26%) |
| Avg Abs Move | 4.85% | 6.07% | 4.47% | 6.50% |
COLL has exhibited substantial volatility around earnings announcements, with an average absolute Day 0 move of 4.85% and Day +1 move of 4.47%. The most recent earnings release on May 7, 2026, produced the largest reaction in the dataset, with a Day 0 surge of +7.72% followed by a Day 1 pullback of -3.89%. This pattern of strong initial reactions followed by partial reversals has been common, as seen in the November 2025 report which jumped +13.42% on Day 0 before adding another +4.03% on Day 1.
The directional pattern shows COLL tends to move sharply higher on earnings beats, with four of the last eight reports producing Day 0 gains exceeding 7%. However, the stock has also demonstrated vulnerability to profit-taking, with several instances of Day 1 reversals even after positive initial reactions. The February 2026 report stands out as particularly volatile, dropping -3.34% on Day 0 and extending losses to -5.77% by Day 1, coinciding with the Q4 2025 earnings miss. Investors should prepare for significant price movement, with historical ranges suggesting swings of 6-7% are typical regardless of direction.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 17) |
| Expected Move | $0.00 (0.00%) |
| Expected Range | $35.73 to $35.73 |
| Implied Volatility | 73.76% |
The options market is not currently pricing in a specific expected move for the upcoming earnings announcement, which is unusual given COLL's historical volatility around earnings. The average historical Day 0 move of 4.85% and Day +1 move of 4.47% suggest investors should anticipate meaningful price action even without explicit options-implied guidance.
Part 3: What Analysts Are Saying
Analysts maintain a bullish stance on Collegium Pharmaceutical with an average rating of 4.29 out of 5.00, though sentiment has deteriorated slightly from 4.57 one month ago. The current consensus includes 4 Strong Buy ratings, 1 Moderate Buy, and 2 Hold ratings, with no sell recommendations. However, the shift from 5 Strong Buys to 4 over the past month indicates some analysts have tempered their enthusiasm.
The average price target of $54.33 implies substantial upside of approximately 52% from the current price of $35.74, with individual targets ranging from a low of $45.00 to a high of $60.00. This wide range reflects differing views on the company's growth trajectory and ability to expand beyond its core Xtampza franchise. The deterioration in sentiment comes despite COLL's recent strong earnings performance, suggesting analysts may be concerned about the sustainability of growth or facing increased uncertainty about competitive dynamics in the pain management market.
The consensus remains constructive overall, with 5 of 7 analysts rating the stock a buy or better, but the recent downgrade activity and the presence of two hold ratings indicate some caution is creeping into the analyst community heading into this earnings report.
Part 4: Technical Picture
The Barchart Technical Opinion shows a Buy signal at 8%, unchanged from last week but representing a significant improvement from the Sell signal at 24% registered one month ago. This shift from negative to positive territory suggests improving technical momentum as the stock heads into earnings.
Timeframe Analysis:
- Short-term (50% Buy): Moderate buy signal indicates positive near-term momentum with some mixed technical factors
- Medium-term (Hold): Neutral reading suggests the intermediate trend is in a consolidation phase without clear directional bias
- Long-term (50% Sell): Moderate sell signal reflects underlying weakness in the longer-term trend structure
Trend Characteristics: The trend is characterized as weak in strength and at its weakest directional point, suggesting COLL is in a fragile technical environment where earnings results could determine the next significant move.
The stock is trading at $35.74, positioned above its 5-day ($35.68), 10-day ($35.69), 20-day ($35.65), 50-day ($34.88), and 100-day ($34.59) moving averages, indicating short- to intermediate-term strength. However, the price remains below the 200-day moving average of $39.37, confirming the longer-term weakness identified in the technical signals.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $35.68 | 50-Day MA | $34.88 |
| 10-Day MA | $35.69 | 100-Day MA | $34.59 |
| 20-Day MA | $35.65 | 200-Day MA | $39.37 |
The technical setup heading into earnings is mixed, with short-term momentum indicators supportive but longer-term structure still impaired. The stock's position above all shorter-term moving averages provides a cushion of support, while the 200-day moving average at $39.37 represents a key resistance level that would need to be reclaimed to confirm a broader trend reversal. Given the weak trend characteristics and COLL's history of volatile post-earnings moves averaging nearly 5%, the technical picture suggests the stock is vulnerable to sharp moves in either direction depending on results and guidance. The recent improvement from sell to buy territory may attract momentum traders, but the lack of strong conviction in the signals means technical support could evaporate quickly on any disappointment.
